Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 59, Issue 6, Pages 491-504Publisher
ELSEVIER
DOI: 10.1016/j.addr.2007.04.008
Keywords
solid lipid nanoparticles; polymer lipid hybrid nanoparticles; chemotherapy; anticancer drug delivery; chemosensitizers; overcoming multidrug esistance
Categories
Ask authors/readers for more resources
The prospect of improved cancer chemotherapy using solid lipid nanoparticles (SLN) as a drug delivery system is promising. Several obstacles frequently encountered with anticancer compounds, such as normal tissue toxicity, poor specificity and stability and a high incidence of drug-resistant tumor cells, are at least partially overcome by delivering them using SLN. The emergence of the newer forms of SLN such as polymerlipid hybrid nanoparticles, nanostructured lipid carriers and long-circulating SLN may further expand the role of this versatile drug carrier in cancer treatment. This review focuses on the current use of SLN for the encapsulation and delivery of cytotoxic anticancer compounds. It also discusses more recent trends in the use of SLN as vehicles for delivery of chemosensitizers and cytotoxic therapeutic molecules. It is anticipated that, in the near future, SLN will be further improved to deliver anticancer compounds in a more efficient, specific and safer manner. (c) 2007 Elsevier B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available